iShares Biotechnology ETF
854 hedge funds and large institutions have $4.68B invested in iShares Biotechnology ETF in 2022 Q2 according to their latest regulatory filings, with 75 funds opening new positions, 220 increasing their positions, 332 reducing their positions, and 98 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
23% less first-time investments, than exits
New positions opened: 75 | Existing positions closed: 98
26% less call options, than puts
Call options by funds: $216M | Put options by funds: $294M
34% less repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 332
Holders
854
Holding in Top 10
15
Calls
$216M
Puts
$294M
Top Buyers
| 1 | +$49.6M | |
| 2 | +$33.4M | |
| 3 | +$23.8M | |
| 4 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$20.2M |
| 5 |
D
Diversified
Wilmington,
Delaware
|
+$17.8M |
Top Sellers
| 1 | -$139M | |
| 2 | -$46M | |
| 3 | -$35.8M | |
| 4 |
Two Sigma Investments
New York
|
-$35.5M |
| 5 |
JG
Jefferies Group
New York
|
-$29.1M |